# CJC-1295 Dosage in Published Studies: Phase 1 and Phase 2 Doses, Routes, Frequencies

> CJC-1295 dosage in the published medical literature: Teichman 2006 used ascending subcutaneous doses of 30, 60, 125, and 250 mcg/kg in healthy adults. A research-context summary.

_PART III — THE DOSE RECORD_

**CJC-1295 Dosage in Published Studies**

Single ascending subcutaneous doses of 30, 60, 125, and 250 mcg/kg in healthy adults. Weekly escalation of 60-240 mcg/kg in the Phase 2 program. The full published dosing record, framed as research context, not as recommendation.

## Doses used in published human trials

The published CJC-1295 dosage record in humans rests on two trials reported by Teichman and colleagues in 2006 and one registered Phase 2 trial in HIV-associated visceral obesity [01][18].

In Teichman 2006, healthy adults aged 21 to 61 received single subcutaneous ascending doses of CJC-1295 (DAC variant) at 30, 60, 125, and 250 mcg/kg [01]. A separate multiple-dose arm of the same paper administered weekly or biweekly subcutaneous doses at 30-60 mcg/kg over 28- to 49-day trial windows [01]. The compound was reported well tolerated at 30-60 mcg/kg; injection-site reactions, transient flushing, and headache were the most frequently logged adverse events [01].

The Phase 2 trial in HIV-associated visceral obesity (NCT00267527, sponsor ConjuChem) used weekly escalating subcutaneous doses across two arms: a low arm at 60, 90, and 120 mcg/kg, and a high arm at 60, 120, and 240 mcg/kg, with twelve-week treatment windows in approximately 192 participants [18]. The trial was terminated before completion (see [developmental history](/about#history)).

## Dosing frequency in published protocols

The DAC and non-DAC variants belong to two different dosing paradigms because their pharmacokinetics differ by two orders of magnitude.

The DAC variant was administered as weekly subcutaneous injection in human Phase 1 and Phase 2 trials, justified by the multi-day plasma half-life produced by covalent serum-albumin binding [01][12]. A single weekly injection at 30-60 mcg/kg maintained mean IGF-1 above baseline across 28-day trial windows.

The non-DAC variant — modified GRF 1-29 — was administered as multiple daily subcutaneous injections, typically 1-3 times per day, in research protocols owing to its 30-minute plasma half-life [13]. The GH pulse from each non-DAC injection lasts roughly 60-90 minutes [13]. The two variants are not interchangeable on a per-injection basis: the non-DAC variant requires frequent dosing to maintain receptor engagement; the DAC variant requires the opposite restraint.

## CJC-1295 Half-Life and Dosing Interval

CJC-1295 half-life splits cleanly along the DAC / non-DAC axis. In Teichman 2006 the estimated plasma half-life of the DAC variant in healthy adults was 5.8 to 8.1 days [01]. The non-DAC variant — modified GRF 1-29 — has a plasma half-life of approximately 30 minutes, extended from the sub-10-minute half-life of native sermorelin by the four DPP-IV-resistant amino-acid substitutions but no further [04][13].

The difference is mechanistic. The DAC linker covalently couples the peptide to Cys34 of serum albumin via maleimide chemistry; albumin's circulating half-life is near 19 days, and the bound peptide rides that turnover [12]. In ConjuChem's preclinical rat assay, immunoreactive albumin-bound CJC-1295 appeared in circulation within 15 minutes of injection and remained detectable beyond 72 hours [03][14]. The 30-minute non-DAC half-life is what DPP-IV resistance alone buys without an albumin carrier.

## Plasma persistence

Plasma persistence is a longer window than functional half-life. The DAC variant remains detectable for roughly 14-21 days due to ongoing albumin binding, and effective GHRHR signaling persists for six to eight days per dose [01][12]. The non-DAC variant clears within hours. Antibody-free nano-LC-HRMS/MS methods reach sub-picogram-per-milliliter sensitivity for the peptide in urine [19], and immunoaffinity-capture LC-MS/MS confirmation methods exist for the albumin-bound DAC variant in plasma [09]; both are the analytical foundations of current WADA enforcement.

## Routes studied

The subcutaneous route dominates the published clinical record. Teichman 2006 used subcutaneous administration for both single-dose and multiple-dose arms [01], as did the Phase 2 lipodystrophy program [18]. Preclinical rat pharmacokinetics used intravenous and subcutaneous administration [03]; rodent screening assays used intraperitoneal as well [03]. No oral, intramuscular, or intranasal CJC-1295 protocols appear in the published human record.

## Stability and reconstitution context

Published technical documentation describes the lyophilized peptide as stable at -20 C [13]. Once reconstituted in bacteriostatic water, the peptide is reported stable refrigerated for several weeks; the DAC variant's maleimide-thiol chemistry is sensitive to oxidation, so the intact peptide is required for in vivo albumin conjugation [13]. This site does not provide reconstitution instructions: that is research-protocol territory, not editorial commentary.

## An editorial caveat on the dose record

The dose figures above are study-administered values in study-defined populations under study-defined monitoring. They are not dosing recommendations. CJC-1295 has not received FDA approval for any indication, and the U.S. Pharmacy Compounding Advisory Committee declined to add it to the 503A Bulks List in December 2024 [20]. The compound is sold widely as a research chemical from suppliers operating outside pharmaceutical-grade quality control. The published peer-reviewed dosing record covers a small number of trials in a small number of populations and does not constitute a clinical dosing standard.

## References

[01] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. — doi:10.1210/jc.2005-1536 · PMID 16352683 · https://pubmed.ncbi.nlm.nih.gov/16352683/
[03] Jetté L, Léger R, Thibaudeau K, et al. Identification of CJC-1295 as a long-lasting GRF analog: rat anterior pituitary cell pharmacology and in vivo plasma persistence (preclinical findings). Endocrinology. 2005;146(7):3052-3058. — doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
[04] Jetté L, Léger R, et al. DPP-IV resistance and extended in vitro plasma stability of tetrasubstituted GHRH(1-29) (preclinical PK data, same source as ref 2/3). Endocrinology. 2005;146(7):3052-3058. — doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
[09] Timms M, Hall N, Levina V, Vine J, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019;11(7):1085-1093. — doi:10.1002/dta.2599 · https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2599
[12] Bridon DP, ConjuChem Inc. Drug Affinity Complex (DAC) technology overview. 2005. — https://www.conjuchem.com/technology/dac.html
[13] Modified GRF (1-29) pharmacology overview. Review article citing original GHRH analog pharmacology literature. 2024. — https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
[14] Jetté L, Léger R, et al. Albumin-bound CJC-1295 immunoreactivity in rat plasma — appears within 15 minutes, persists beyond 72 hours (preclinical PK data, same source as ref 2/3). Endocrinology. 2005;146(7):3052-3058. — doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
[18] ConjuChem Biotechnologies (sponsor). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov identifier NCT00267527. 2007. — https://clinicaltrials.gov/study/NCT00267527
[19] Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. — doi:10.1002/dta.3183 · PMID 34665524 · https://pubmed.ncbi.nlm.nih.gov/34665524/
[20] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Meeting; Bulk Drug Substances Nominated for Inclusion on the 503A Bulk Drug Substances List. December 2024 briefing documents. — https://www.fda.gov/media/183819/download

---

An unrolled scroll of the peer-reviewed CJC-1295 literature, read in sumi-ink and a single vermillion seal — not a clinic, not a pharmacy, not a prescription.